Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 126,423

Document Document Title
WO/2017/113775A1
The present invention provides an application of a triglyceride compound for use in preparing a medicine for treating neurodegenerative diseases.  
WO/2017/114321A1
A traditional Chinese medicine for treating viral encephalitis is prepared from the following raw materials in parts by weight: 4 to 10 parts of coastal glehnia root, 3 to 8 parts of paniculate swallowwort root, 2 to 7 parts of chastetre...  
WO/2017/115815A1
The present invention relates to a therapeutic agent, a medicine and a treatment method for treatment-resistant depression, persistent depression and/or recurrent depression, in each of which a compound represented by formula (1') or a p...  
WO/2017/117158A1
The present disclosure is directed to methods, compositions, and kits for treating amyotrophic lateral sclerosis.  
WO/2017/113289A1
Disclosed are a ginsenoside Rg1 vitreous cavity injection delivery system and a use thereof in preparing a drug for treating glaucomatous optic nerve damage. The delivery system comprises a ginsenoside Rg1 solution and an ultrasonic cont...  
WO/2017/115789A1
Provided are compositions for recovering and/or ameliorating deterioration of physiological functions due to aging. A cell overexpressing GDF6 protein or an miR-17 family member. A composition for treating aging-related symptoms, said co...  
WO/2017/114225A1
The present invention relates to a fused tricyclic γ-amino acid derivative and a pharmaceutical application thereof. Specifically, the present invention relates to a fused tricyclic γ-amino acid derivative depicted by general formula (...  
WO/2017/114260A1
Provided in the present invention are an indoleamine 2,3-dioxygenase 2 inhibitor and applications thereof. Specifically, provided is a compound as represented by formula I of the present invention or a pharmaceutically acceptable salt th...  
WO/2017/113964A1
Provided is a novel stilbene derivative, being a compound having the general formula (I) or general formula (II), or an acceptable salt formed from the compound having the general formula (I) or general formula (II) with an inorganic aci...  
WO/2017/115705A1
[Problem] To provide a medicinal composition that is capable of improving the prognosis after the restart of the patient's own heartbeat even after the passage of a considerably long period of time after the restart of the patient's own ...  
WO/2017/117529A1
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using ...  
WO/2017/107791A1
The present invention relates to a crystal form of a substituted aminopyran compound, and a pharmaceutical composition, a preparation method and a use thereof in the preparation of a drug for treating type II diabetes. In particular, the...  
WO/2017/112917A1
Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A)receptor antagonist and a ...  
WO/2017/111166A1
According to the present invention, a drug for treating an intracellular TDP-43 content-related disease is developed and provided . In the binding of TDP-43 to a specific mt-tRNA, the binding sites of the respective substances are identi...  
WO/2017/111005A1
A tablet which comprises (1) 1-(3-(2-(1-benzothiophen-5- yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and (2) ethyl cellulose, said tablet having excellent elution properties and good moldability, remaining stable during prolonged st...  
WO/2017/112719A1
The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds descr...  
WO/2017/109300A1
The invention relates to a combination product comprising, as active substances, at least melatonin, passion flower, chamomile and lemon balm or a bioequivalent compound thereof for helping individuals relax and/or fall asleep. The inven...  
WO/2017/107907A1
The present invention relates to a condensed ring γ-amino acid derivative and a medical use thereof, and in particular relates to the condensed ring γ-amino acid derivative as shown in formula (I), or a stereisomer, a solvate, a metabo...  
WO/2017/110705A1
The present invention addresses the problem of developing a drug capable of regrowing synapses, which have been damaged and lost due to a neurodegenerative disease, to thereby provide a medicinal composition for preventing or treating a ...  
WO/2017/107242A1
The present invention relates to a pharmaceutical composition and a preparation method and an application thereof. The pharmaceutical composition consists of cycloserine and an adjuvant, wherein the D90 particle diameter of the pharmaceu...  
WO/2017/111668A1
The invention relates to the field of medicine. A preparation for treating exostoses, headaches and cardiac pain comprises turpentine and formaldehyde and additionally contains ethanol 96% in the following ingredient ratio (in ml per 100...  
WO/2017/109095A1
The invention relates to (hetero) cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.  
WO/2017/111052A1
The purpose of the present invention is to provide a medicament for treating an autoimmune disease. The present invention pertains specifically to a therapeutic agent for an autoimmune disease such as HTLV-associated myelopathy, which co...  
WO/2017/111123A1
The present invention enables treatment and/or prevention of dementia, cognitive impairment, and vascular depression by a combination of aripiprazole and cilostazol, or the like. The combination contains aripiprazole and cilostazol, and ...  
WO/2017/109724A1
Disclosed are compounds having the formula (I) wherein Q, X, A, L, B, Q4, R, RA, R5, n and m are as defined herein, and methods of making and using the same.  
WO/2017/108441A1
The present invention is directed to the treatment of cognitive impairment. More in particular, the present invention is directed to the treatment of cognitive impairment associated with aging, Alzheimer's disease or schizophrenia. More ...  
WO/2017/108500A1
The invention relates to a nutritional composition for infants and young children, such as an infant formula or follow-on formula or growing up milk, preferably an infant formula, and comprising a vitamin or mixtures thereof. Thevitamins...  
WO/2017/112889A1
The present invention relates to compositions and methods for treating neurodegenerative conditions using GLP-1r agonists. In certain embodiments, long-acting GLP-1r agonists have neuroprotective and disease modifying effects on the cent...  
WO/2017/107089A1
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the pot...  
WO/2017/107863A1
Disclosed are a composition for treating motor neuron diseases and a use thereof. Each unit of the pharmaceutical composition contains 0.3 to 8 g of L-ornithine or an L-ornithine salt with an L-ornithine content equivalent to 0.3 to 8 g,...  
WO/2017/102893A1
The present invention is concerned with derivatives of 3,5-diphenyl-diazole derivatives, which are effective therapeutic agents for use in treating diseases linked to protein aggregation and/or neurodegenerative diseases such as Alzheime...  
WO/2017/103604A1
The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.  
WO/2017/102717A1
A synthetic nutritional composition comprising a phospholipid and/or a metabolic precursor and/or metabolite thereof for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or br...  
WO/2017/106584A1
Methods of using β3-adrenoceptor agonists for treatment of central nervous system and mental disorders are disclosed. In particular, the invention relates to methods of treating central nervous system and mental disorders with selective...  
WO/2017/102721A1
The invention relates to a nutritional connposition for infants and young children, such as an infant formula or follow-on formula or growing up milk, preferably an infant formula, and comprising choline. The choline promotes and/or supp...  
WO/2017/102718A1
The invention relates to a nutritional composition for infants and young children, such as an infant formula or follow-on formula or growing up milk, preferably an infant formula, and comprising a fatty acid derivative or mixtures thereo...  
WO/2017/102968A1
Compositions can comprise the flavanol metabolite 4'-O-glucuronide epicatechin (4GEC). In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body,...  
WO/2017/103224A1
The present invention concerns an agonist of a MCH receptor for use for preventing, slowing or stopping weight loss or promoting weight gain in a subject suffering from ALS.  
WO/2017/100896A1
The present disclosure concerns non-agglomerating bioconjugates of amylin, amylin-mimetic compounds, and combinations comprising the same, wherein said bioconjugate contains at least one acyl unit. Methodology of making and using are pro...  
WO/2017/106288A1
Described herein are novel compounds and methods for the treatment and/or prevention of cerebral amyloidoses such as Alzheimer's disease (AD) and/or cerebral amyloid angiopathy (CAA).  
WO/2017/100938A1
The present application provides an inhibitory compound, such as a peptide, and methods for using the inhibitory compound in the treatment, diagnosis or monitoring of cognitive and mood disorders that are typically associated with memory...  
WO/2017/102719A1
The invention relates to a nutritional composition for infants and young children, such as an infant formula or follow-on formula or growing up milk, preferably an infant formula, and comprising a mineral or mixtures thereof. The mineral...  
WO/2017/101889A1
Disclosed is a Chinese traditional medicine composition for treating breast hyperplasia and other breast diseases, and the raw materials thereof comprise Cyperus rotundus , Angelica sinensis , Ligusticum wallichii , white peony root and ...  
WO/2017/102714A1
A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectua...  
WO/2017/106641A1
The present disclosure relates to solid state forms of Brexpiprazole, as well as uses and compositions comprising the solid state forms.  
WO/2017/102965A1
Compositions can comprise the flavanol metabolite 3'-O-glucuronide epicatechin (3GEC). In some embodiments, the amount of 3GEC is effective to increase energy expenditure, sympathetic nervous system activity, and/or fat oxidation. Such a...  
WO/2017/104777A1
A purpose of the present invention is to provide: a composition for inhibiting carnosine dipeptidase, use of said composition for inhibiting carnosine dipeptidase, and a method for inhibiting carnosine dipeptidase. Another purpose of the...  
WO/2017/101887A1
A healthcare pharmaceutical preparation having magnesium supplementation and anti-oxidation effects, and a preparation method for the healthcare pharmaceutical preparation. The healthcare pharmaceutical preparation comprises a main effec...  
WO/2017/101884A1
Disclosed are an indolamine 2,3-dioxygenase inhibitor having the structure of formula (I) and a preparation method and use thereof. The indolamine 2,3-dioxygenase (IDO) inhibitor is a (Z)-N'-hydroxy-N-benzamidine derivative, has a very h...  
WO/2017/101796A1
The present application relates to a phthalazinone derivative, and a preparation method and a use thereof. In particular, the present application relates to a compound of formula I, and a prodrug, a metabolite form, a pharmaceutically ac...  

Matches 451 - 500 out of 126,423